Actualités

The Phase 2 trial met both primary endpoints on symptom frequency and severity

AbCellera (NASDAQ:ABCL) shares jumped 22% on Monday after the biotechnology company announced positive topline results from a Phase 2 clinical trial evaluating ABCL635 as a potential treatment for moderate-to-severe vasomotor symptoms associated with menopause. The study achieved its primary efficacy endpoints, demonstrating statistically significant reductions in both the frequency and severity of moderate-to-severe vasomotor symptoms at week four following a single dose compared with placebo.

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.

ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, Stifel raised the firm’s price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $8 from $7 and kept a Buy rating on the shares. The firm said preliminary safety, pharmacokinetic, and pharmacodynamic data from the […]

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?